These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15613899)

  • 21. Tumour macrophages as potential targets of bisphosphonates.
    Rogers TL; Holen I
    J Transl Med; 2011 Oct; 9():177. PubMed ID: 22005011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates in cancer therapy.
    Green JR
    Curr Opin Oncol; 2002 Nov; 14(6):609-15. PubMed ID: 12409650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.
    Van Acker HH; Anguille S; Willemen Y; Smits EL; Van Tendeloo VF
    Pharmacol Ther; 2016 Feb; 158():24-40. PubMed ID: 26617219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates in cancer therapy.
    Stresing V; Daubiné F; Benzaid I; Mönkkönen H; Clézardin P
    Cancer Lett; 2007 Nov; 257(1):16-35. PubMed ID: 17697748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
    Clézardin P
    Bone; 2011 Jan; 48(1):71-9. PubMed ID: 20655399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence.
    Santini D; Stumbo L; Spoto C; D'Onofrio L; Pantano F; Iuliani M; Fioramonti M; Zoccoli A; Ribelli G; Virzì V; Vincenzi B; Tonini G
    Breast Cancer Res; 2015 Sep; 17(1):121. PubMed ID: 26328589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nitrogen-containing bisphosphonates and cancer immunotherapy.
    Clézardin P; Massaia M
    Curr Pharm Des; 2010; 16(27):3007-2014. PubMed ID: 20722623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.
    Tsubaki M; Itoh T; Satou T; Imano M; Komai M; Ogawa N; Mukai J; Nishida S
    Biochem Pharmacol; 2013 Jan; 85(2):163-72. PubMed ID: 23085435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
    J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential anticancer properties of bisphosphonates: insights from preclinical studies.
    Clezardin P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):102-13. PubMed ID: 21864232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonates in preclinical bone oncology.
    Clézardin P; Benzaïd I; Croucher PI
    Bone; 2011 Jul; 49(1):66-70. PubMed ID: 21145441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New role for an established drug? Bisphosphonates as potential anticancer agents.
    Koul HK; Koul S; Meacham RB
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):111-9. PubMed ID: 21876554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.
    Dedes PG; Gialeli Ch; Tsonis AI; Kanakis I; Theocharis AD; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2012 Dec; 1820(12):1926-39. PubMed ID: 22884656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S; Kamiya S; Ono K
    Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.
    Holen I; Coleman RE
    Breast Cancer Res; 2010; 12(6):214. PubMed ID: 21176176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor effects and anticancer applications of bisphosphonates.
    Morgan G; Lipton A
    Semin Oncol; 2010 Oct; 37 Suppl 2():S30-40. PubMed ID: 21111246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoledronic acid - a multiplicity of anti-cancer action.
    Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
    Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.
    Desai B; Rogers MJ; Chellaiah MA
    Mol Cancer; 2007 Mar; 6():18. PubMed ID: 17343740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
    J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.